Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Deborah Collyar: What's In It for Patients?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Peter Clark, MA, MD, FRCP: A Payer Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Advertisement

Advertisement

Jan

19

Today In Oncology

Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides

HCC LLM Advice and Treatment Concordance

Can a Genetic Variant Affect the Efficacy of Abiraterone

Breast Cancer Risk May Be Linked to Physical Activity Levels in Adolescence

What Is Causing a Rise in Early-Onset Gastrointestinal Cancers, Including Pancreatic Cancer?

Advertisement

© 2026 HSP News Service, L.L.C.